885 - The efficacy of gemcitabine-based chemoradiotherapy for the definitive treatment of locally-advanced bladder cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Urothelial Cancers
Surgery and/or Radiotherapy of Cancer
Presenter Meral Kurt
Authors M. Kurt1, H. Ozturk2, S. Cetintas3, E. Kurt4, L. Ozkan3
  • 1Radiation Oncology, Uludag University School of Medicine, 16059 - BURSA/TR
  • 2Radiation Oncology, Yunus Emre Hastahanesi, Eskisehir/TR
  • 3Radiation Oncology, Uludag University, Bursa/TR
  • 4Medical Oncology, Uludag University, BURSA/TR



The aim of the present study was to investigate the efficacy and the tolerability of gemcitabine-based chemoradiotherapy (CRT) for the definitive treatment of locally-advanced bladder cancer.


Patients with the diagnosis of locally-advanced, transitional cell bladder cancer, who had been treated with gemcitabine-based CRT at the Radiation Oncology department of the Uludag University between January 2005 and January 2009, were enrolled in this retrospective analysis. After maximal transurethral resection of tumor, three-dimensional radiotherapy (RT) was administered at an initial dose of 45 Gy to the primary tumor site plus regional lymphatics followed by a 20 Gy boost to the whole bladder with additional 2 cm margins (1.8 Gy daily fractions, five days a week). All patients received weekly gemcitabine at a dose of 350 mg/m2 on Mondays during the course of RT. Response evaluations were performed every three months by systoscopic examinations and appropriate radiologic studies.


A total of 20 patients were entered into the study. There were 18 male and 2 female with a median age of 72 (range: 40–78). The median disease-free survival was 35,0 ± 8,2 months (95% CI: 18,7–51,2), and the median overall survival was 37,0 ± 4,4 (95% CI: 28,3–45,7). Acute treatment-related grade ¾ hematologic toxicities were seen in 4 patients (20%). Although 3 patients (15%) exhibited grade ½ gastrointestinal toxicities, there were no grade ¾ non-hematologic toxicities.


Gemcitabine-based definitive CRT seems to be effective and tolerable treatment option for the treatment of locally-advanced bladder cancer.


All authors have declared no conflicts of interest.